))
1: Episode I: Allan Gobbs, ATEM Capital
Manage episode 428009276 series 3585315
コンテンツは Venture Vitals by Caelestinus によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Venture Vitals by Caelestinus またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
In this compelling episode of Venture Vitals, Tomas and Evgeny sit down with Allan Gobbs, Managing Partner at NY-based Life Sciences venture firm ATEM Capital, to uncover the secrets of health tech investment success. Join us as Allan shares his extraordinary journey from managing a $760M partnership to celebrating multiple NASDAQ listings and high-profile exits.
• Allan’s path to becoming a venture capital virtuoso in digital health.
• Essential advice for aspiring venture capitalists aiming to break into the industry.
• Key components of a successful startup pitch to secure investment from ATEM Capital.
• Insights into Allan’s preferred investment stages and strategies for startups.
• Distinctions between investing in digital health versus other tech sectors.
• Allan’s most triumphant investment stories and the journeys to successful exits.
• Predictions on the next big revolution in digital health.
• Crucial advice for health tech founders and investors.
Allan Gobbs
Allan Gobbs is a Managing Partner at NY-based Life Sciences venture firm ATEM Capital. Prior to ATEM he managed a $760M partnership with Domain Associates. Over the last few years Allan had 5 of his portfolio companies listed on NASDAQ, notably Atea Pharmaceuticals, which yielded a 30x return at IPO, Marinus and Syndax. Four of his portfolio companies have been sold, including Tobira Therapeutics, which was acquired by Allergan at a record 19x premium. Before ATEM Capital, Gobbs was a VP at Barclays Capital and Dresdner Kleinwort, where he advised on M&A and capital market transactions exceeding $20B. Allan is a member of the Forbes Business Council, the Private Directors Association, and the Review Committee of the National Cancer Institute at NIH. More info via https://atemcap.com/
• Allan’s path to becoming a venture capital virtuoso in digital health.
• Essential advice for aspiring venture capitalists aiming to break into the industry.
• Key components of a successful startup pitch to secure investment from ATEM Capital.
• Insights into Allan’s preferred investment stages and strategies for startups.
• Distinctions between investing in digital health versus other tech sectors.
• Allan’s most triumphant investment stories and the journeys to successful exits.
• Predictions on the next big revolution in digital health.
• Crucial advice for health tech founders and investors.
Allan Gobbs
Allan Gobbs is a Managing Partner at NY-based Life Sciences venture firm ATEM Capital. Prior to ATEM he managed a $760M partnership with Domain Associates. Over the last few years Allan had 5 of his portfolio companies listed on NASDAQ, notably Atea Pharmaceuticals, which yielded a 30x return at IPO, Marinus and Syndax. Four of his portfolio companies have been sold, including Tobira Therapeutics, which was acquired by Allergan at a record 19x premium. Before ATEM Capital, Gobbs was a VP at Barclays Capital and Dresdner Kleinwort, where he advised on M&A and capital market transactions exceeding $20B. Allan is a member of the Forbes Business Council, the Private Directors Association, and the Review Committee of the National Cancer Institute at NIH. More info via https://atemcap.com/
4 つのエピソード
シェア
